WO2004039950A3 - Activation de lymphocytes specifiques du vhc - Google Patents

Activation de lymphocytes specifiques du vhc Download PDF

Info

Publication number
WO2004039950A3
WO2004039950A3 PCT/US2003/033610 US0333610W WO2004039950A3 WO 2004039950 A3 WO2004039950 A3 WO 2004039950A3 US 0333610 W US0333610 W US 0333610W WO 2004039950 A3 WO2004039950 A3 WO 2004039950A3
Authority
WO
WIPO (PCT)
Prior art keywords
hcv
cells
specific
activation
specific cells
Prior art date
Application number
PCT/US2003/033610
Other languages
English (en)
Other versions
WO2004039950A2 (fr
Inventor
Michael Houghton
Steve Coates
Mark Selby
Xavier Paliard
Original Assignee
Chiron Corp
Michael Houghton
Steve Coates
Mark Selby
Xavier Paliard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp, Michael Houghton, Steve Coates, Mark Selby, Xavier Paliard filed Critical Chiron Corp
Priority to EP03781368A priority Critical patent/EP1576125A4/fr
Priority to AU2003287188A priority patent/AU2003287188A1/en
Priority to CA002505611A priority patent/CA2505611A1/fr
Publication of WO2004039950A2 publication Critical patent/WO2004039950A2/fr
Publication of WO2004039950A3 publication Critical patent/WO2004039950A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne un procédé d'activation de lymphocytes T spécifiques du virus de l'hépatite C (VHC), notamment des lymphocytes T CD4+ et CD8+. Les lymphocytes T spécifiques du VHC sont activés au moyen de protéines de fusion comprenant des polypeptides du VHC NS3, NS4, NS5a, et NS5b, des polynucléotides codant lesdites protéines de fusion, ou des compositions polypeptidiques ou polynucléotidiques contenant les composants individuels de ces fusions. Le procédé de l'invention peut être utilisé dans des systèmes modèles pour développer des compositions immunogènes spécifiques du VHC, ainsi que pour immuniser un mammifère contre le VHC.
PCT/US2003/033610 2002-10-25 2003-10-24 Activation de lymphocytes specifiques du vhc WO2004039950A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP03781368A EP1576125A4 (fr) 2002-10-25 2003-10-24 Activation de lymphocytes specifiques du vhc
AU2003287188A AU2003287188A1 (en) 2002-10-25 2003-10-24 Activation of hcv-specific cells
CA002505611A CA2505611A1 (fr) 2002-10-25 2003-10-24 Activation de lymphocytes specifiques du vhc

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28134102A 2002-10-25 2002-10-25
US10/281,341 2002-10-25

Publications (2)

Publication Number Publication Date
WO2004039950A2 WO2004039950A2 (fr) 2004-05-13
WO2004039950A3 true WO2004039950A3 (fr) 2007-11-22

Family

ID=32228760

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/033610 WO2004039950A2 (fr) 2002-10-25 2003-10-24 Activation de lymphocytes specifiques du vhc

Country Status (4)

Country Link
EP (1) EP1576125A4 (fr)
AU (1) AU2003287188A1 (fr)
CA (1) CA2505611A1 (fr)
WO (1) WO2004039950A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776343B1 (en) 1999-02-17 2010-08-17 Csl Limited Immunogenic complexes and methods relating thereto
US20070264285A1 (en) * 2003-04-25 2007-11-15 O'hagan Derek Compositions Comprising Cationic Microparticles And Hcv B1e2 Dna And Methods Of Use Thereof
CA2566725A1 (fr) * 2004-05-17 2005-12-01 Chiron Corporation Domaine ns5 du virus de l'hepatite c tronque et proteines hybrides comprenant ce dernier
AU2005335104C1 (en) * 2004-07-18 2010-10-28 Csl Limited Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
US8216590B2 (en) 2006-08-25 2012-07-10 Novartis Ag HCV fusion polypeptides
US9551714B2 (en) 2010-06-25 2017-01-24 Abbott Laboratories Materials and methods for assay of anti-hepatitis C virus (HCV) antibodies
CN103819565B (zh) * 2014-02-26 2016-11-09 广州万孚生物技术股份有限公司 Hcv重组融合抗原及其表达基因和制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996038474A2 (fr) * 1995-05-31 1996-12-05 Bionova Corporation Diagnostic de et vaccination contre un virus a arn double brin positif a l'aide d'un polypeptide isole et non traite
US5747239A (en) * 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
US6312889B1 (en) * 1990-04-04 2001-11-06 Chiron Corporation Combinations of hepatitis c virus (HCV) antigens for use in immunoassays for anti-HCV antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0935662T3 (da) * 1996-05-24 2006-03-06 Chiron Corp Fusionsprotein med multiple epitoper
AU2003248818A1 (en) * 2002-07-02 2004-01-23 Novartis Vaccines And Diagnostics, Inc. Hcv fusion proteins with modified ns3 domains

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747239A (en) * 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
US6312889B1 (en) * 1990-04-04 2001-11-06 Chiron Corporation Combinations of hepatitis c virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
WO1996038474A2 (fr) * 1995-05-31 1996-12-05 Bionova Corporation Diagnostic de et vaccination contre un virus a arn double brin positif a l'aide d'un polypeptide isole et non traite

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1576125A4 *

Also Published As

Publication number Publication date
AU2003287188A8 (en) 2004-05-25
EP1576125A2 (fr) 2005-09-21
AU2003287188A1 (en) 2004-05-25
EP1576125A4 (fr) 2008-09-03
WO2004039950A2 (fr) 2004-05-13
CA2505611A1 (fr) 2004-05-13

Similar Documents

Publication Publication Date Title
WO2001030812A3 (fr) Activation de lymphocytes t specifiques au virus de l'hepatite c
WO2004111082A3 (fr) Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
Xu et al. Bovine viral diarrhea virus NS3 serine proteinase: polyprotein cleavage sites, cofactor requirements, and molecular model of an enzyme essential for pestivirus replication
Collett Molecular genetics of pestiviruses
WO2005113837A3 (fr) Domaine ns5 du virus de l'hepatite c tronque et proteines hybrides comprenant ce dernier
SG165155A1 (en) Novel flavivirus antigens
WO2004005473A3 (fr) Proteines hybrides de vhc a domaines ns3 modifies
HK1112481A1 (en) Modified human hepatitis c virus genomic rna having autonomous replicative competence
JP2008516610A5 (fr)
WO2006096459A3 (fr) Virus infectieux chimeriques de l'hepatite c, leurs procedes de production et leurs methodes d'utilisation
WO1999038888A3 (fr) Inhibiteurs peptidiques de l'activite de la serine protease associee a la proteine ns53 de vhc, leurs utilisations correspondantes et leur procede de production
EP0939128A3 (fr) Isolats de VHC
EP1930416A4 (fr) Nouvelle particule humaine recombinee de type du virus de l'hepatite c et procede de production associe
WO2009014216A1 (fr) Anticorps ayant une activité inhibitrice sur l'infection par le virus de l'hépatite c (vhc) et son utilisation
NZ518999A (en) Vaccine compositions
ATE555800T1 (de) Zusammensetzung mit dem polyprotein ns3/ns4 und dem polypeptid ns5b von hcv, expressionsvektoren mit den entsprechenden nukleinsäuresequenzen und ihre therapeutische verwendung
WO2007081848A3 (fr) Activations de lymphocytes t spécifiques du vhc
WO2004039950A3 (fr) Activation de lymphocytes specifiques du vhc
WO2001038360A3 (fr) Polypeptide non structurel du virus de l'hepatite c
WO2004048402A3 (fr) Gene de fusion ns3/4a non structurel a codons optimises du virus de l'hepatite c
DK0644894T3 (da) Peptid til stimulering af Hepatitis C virus-specifikke cytotoksiske T-lymfocytter
JP2006518331A5 (fr)
Kim et al. Towards defining a minimal functional domain for NTPase and RNA helicase activities of the hepatitis C virus NS3 protein
JP2005532064A5 (fr)
WO1996038474A3 (fr) Diagnostic de et vaccination contre un virus a arn double brin positif a l'aide d'un polypeptide isole et non traite

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2505611

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003781368

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2003781368

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP